Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Efgartigimod in Adult Patients With Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) Who Completed Study ARGX-113-2104

NCT05918978 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT05918978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Efgartigimod in Adult Patients With Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) Who Completed Study ARGX-113-2104
Lead sponsor
argenx
Phase
Phase 2
Overall status
Terminated
Start date
June 20, 2023
Completion date
August 15, 2024
Enrollment
33 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

post-covid postural orthostatic tachycardia syndrome postural orthostatic tachycardia syndrome